

IN THE CLAIMS:

Please replace all previously pending claims with the listing of claims set forth below:

- 1-14. (Canceled)
15. (New) A method for treating lipodystrophy in a patient comprising administering an effective amount of a docosahexaenoic acid of animal, plant or microorganism-produced origin, wherein the patient is concomitantly receiving an active anti-retroviral therapy (HAART), thereby treating lipodystrophy in the patient.
16. (New) The method of claim 15, wherein the effective amount of the docosahexaenoic acid is higher than or equal to 100 mg/day.
17. (New) The method of claim 15, wherein the effective amount of the docosahexaenoic acid is 4 grams/day.
18. (New) The method of any of claim 15, where the administration of the docosahexaenoic acid promotes adipocytary differentiation.
19. (New) The method of claim 15, wherein the docosahexaenoic acid has hypolipemiant activity.
20. (New) The method of claim 15, wherein the docosahexaenoic acid reduces the alpha tumour necrosis factor.
21. (New) The method of claim 15, wherein the docosahexaenoic acid has antihypertensive activity.
22. (New) The method of claim 15, wherein the docosahexaenoic acid is capable of inhibiting the toxic effects caused by the administration of an antiretroviral drug.
23. (New) The method of claim 15, wherein the docosahexaenoic acid is present in a concentration which ranges between 5% and 100% (w/w).
24. (New) The method of claim 23, wherein the docosahexaenoic acid is present in a concentration which ranges between 50% and 100% (w/w).

25. (New) The method of claim 15, wherein the docosahexaenoic acid is administered orally.
26. (New) The method of claim 15, wherein the docosahexaenoic acid is administered parenterally.
27. (New) The method of claim 15, wherein the patient is a human patient.
28. (New) The method of claim 27, wherein the human patient is infected with the HIV virus.